Evidence map›Paper›PMID 37198545›Full record

ArticleCellular & molecular biology letters2023

Profiling the impact of the promoters on CRISPR-Cas12a system in human cells.

Jinhe Li, Qinchun Liang, HuaPing Zhou, Ming Zhou, Hongxin Huang

Erratum issuedOpen access · goldAbstract readLetter
In one paragraph

Article in Cellular & molecular biology letters, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 1 country.

Jinhe Li *The Third Affiliated Hospital of Southern Medical University, Guangzhou, 510630, China.
Qinchun Liang *The Third Affiliated Hospital of Southern Medical University, Guangzhou, 510630, China.
HuaPing ZhouAffiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou, 510095, China.
Ming ZhouAffiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou, 510095, China. zhouming@gzhmu.edu.cn.
Hongxin HuangAffiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou, 510095, China. huanghx08@gzhmu.edu.cn.ORCID http://orcid.org/0000-0002-8656-4266
Guangzhou Medical University Cancer Hospital · CNGuangzhou Medical University · CNGuangzhou University · CNThird Affiliated Hospital of Southern Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The plasmid vector platform is the most commonly used vector for the expression of the versatile CRISPR-Cas technique and the promoter is a crucial element for the expression vector, thus profiling the impact of the promoters on CRISPR editors provides the basic information for the gene-editing toolkits and can be a guideline for its design. Herein, we made a parallel comparison among four commonly used promoters (CAG, ~ 1700 bp; EF1a core, ~ 210 bp; CMV, ~ 500 bp; and PGK, ~ 500 bp) in CRISPR-Cas12a system in mammalian cells to explore the impact of promoters on this powerful tool. We found that without badly damaging targeting specificity, the CAG promoter-driving Cas12a editor exhibited the most active (efficiency takes as 100%, specificity index =  ~ 75%) in genomic cleavage, multiplex editing, transcriptional activation, and base editing, followed by promoter CMV (efficiency = 70 ~ 90% (vs CAG), specificity index =  ~ 78%), and then EF1a core and PGK (both efficiency = 40-60%, vs CAG) but with higher specificity (specificity index =  ~ 84% and ~ 82%, respectively). Therefore, CAG is recommended in the CRISPR-Cas12a system for the applications that need a robust editing activity but without size limitation, CMV mostly can be an alternative for CAG when requiring a smaller space, EF1a is similar to PGK with relatively high specificity, but has a smaller size, thus is more suitable for in vivo therapeutic applications. The data outlined the properties of the widely used promoters in the CRISPR-Cas12a system, which can be a guide for its applications and can be a useful resource for the gene-editing field.

Indexed as

CRISPR-Associated ProteinsCytomegalovirus InfectionsAnimalsCRISPR-Cas SystemsGene EditingGenetic VectorsHumansMammalsCRISPR-Associated ProteinsComparisonCRISPR-Cas systemImpactPlasmid designPromoters

Identifiers

PMID37198545
PMCPMC10190037
OpenAlexW4377010794

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.